Guidance for switching from off-label antipsychotics to pimavanserin for Parkinson’s disease psychosis: an expert consensus


In the original publication “Guidance for switching from off-label antipsychotics to pimavanserin for Parkinson’s disease psychosis: an expert consensus,” by Black et al. (2018), the authors regret the errors found in Table 1; Boxes 1, 3, and 4; and Figure 1. The correct Table 1, Boxes 1, 3, and 4, and Figure 1 are given below.

### TABLE 1. Receptor binding affinities for select antipsychotic agents

<table>
<thead>
<tr>
<th>Drug</th>
<th>(D_2)</th>
<th>5-HT1A</th>
<th>5-HT2A</th>
<th>D1A</th>
<th>D2C</th>
<th>M1 (central)</th>
<th>M2 (peripheral)</th>
<th>H1</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pimavanserin</td>
<td>++</td>
<td>+</td>
<td>+++++</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Haloperidol</td>
<td>+++</td>
<td>-</td>
<td>+++</td>
<td>++</td>
<td>++</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Clozapine</td>
<td>++</td>
<td>+</td>
<td>+++</td>
<td>+</td>
<td>++</td>
<td>+++</td>
<td>+++</td>
<td>+</td>
</tr>
<tr>
<td>Quetiapine</td>
<td>-</td>
<td>-</td>
<td>+</td>
<td>-</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>Olanzapine</td>
<td>++++</td>
<td>-</td>
<td>+</td>
<td>-</td>
<td>-</td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
</tbody>
</table>

**Effects of blockade**

- Antipsychotic, anticholinergic, 
- 5HT2A/5HT3 receptor antagonist, 
- D2 receptor antagonist, 
- Dopamine D2 receptor antagonist

- Pimavanserin is a selective 5HT2A receptor antagonist.

**Potential Withdrawal/Rebound Effects**

- Anorexia, nausea, vomiting, diarrhea, withdrawal delirium
- Severe extrapyramidal symptoms
- Severe hypertension
- Hypotension
- Angina, conduction defects, arrhythmias, orthostatic hypotension
- Dystonia, akathisia, hyperreflexia, chorea, dyskinesia, nystagmus
- Weight gain
- Headache

+ weak binding affinity (100>Ki<1000)
++ moderate binding affinity (10>Ki<100)
+++ strong binding affinity (1>Ki<10)
++++ very strong binding affinity (Ki<1)

**Abbreviations:**
- 5-HT = serotonin,
- \(\alpha\) = adrenergic,
- D = dopamine,
- H = histamine,
- M = muscarinic.

**Ki (nM)** values are derived from functional antagonist R-SAT\(\text{TM}\) assays (ACADIA, San Diego, CA, USA).

“-” denotes no response.

In addition, the authors would like to make the following text corrections and clarifications:

Page 405:
- The MDS EBM was published in 2011.

Page 406:
- The doses in the early phase 2b/3 study were placebo, 8.5, and 34 mg/d.
- The \( P \)-value for the hallucination and delusions subscales was 0.0012.
- Sleep quality, caregiver burden, etc. were exploratory outcomes.

Page 407:
- The QT prolongation for pimavanserin is 5-8 msec.
- The original publication has been corrected to reflect these changes.

REFERENCE: